351 related articles for article (PubMed ID: 32767974)
1. Loss of survival advantage for deficient mismatch repair in patients with advanced colorectal cancer may be caused by changes in prognostic value of CD8+T cell.
Wang B; Li F; Guo L; Lu S; Ma J; Ma Y; Meng Y; Wang J; Zhou X; Fu W
World J Surg Oncol; 2020 Aug; 18(1):196. PubMed ID: 32767974
[TBL] [Abstract][Full Text] [Related]
2. Intertumoral Heterogeneity of CD3
Yoon HH; Shi Q; Heying EN; Muranyi A; Bredno J; Ough F; Djalilvand A; Clements J; Bowermaster R; Liu WW; Barnes M; Alberts SR; Shanmugam K; Sinicrope FA
Clin Cancer Res; 2019 Jan; 25(1):125-133. PubMed ID: 30301825
[TBL] [Abstract][Full Text] [Related]
3. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
[TBL] [Abstract][Full Text] [Related]
4. The Alteration of T-Cell Heterogeneity and PD-L1 Colocalization During dMMR Colorectal Cancer Progression Defined by Multiplex Immunohistochemistry.
Yan H; Li Y; Wang X; Qian J; Xu M; Peng J; Huang D
Front Oncol; 2022; 12():867658. PubMed ID: 35669431
[TBL] [Abstract][Full Text] [Related]
5. High density of cytotoxic T-lymphocytes is linked to tumoral PD-L1 expression regardless of the mismatch repair status in colorectal cancer.
Möller K; Blessin NC; Höflmayer D; Büscheck F; Luebke AM; Kluth M; Hube-Magg C; Zalewski K; Hinsch A; Neipp M; Mofid H; Lárusson H; Daniels T; Isbert C; Coerper S; Ditterich D; Rupprecht H; Goetz A; Bernreuther C; Sauter G; Uhlig R; Wilczak W; Simon R; Steurer S; Minner S; Burandt E; Krech T; Perez D; Izbicki JR; Clauditz TS; Marx AH
Acta Oncol; 2021 Sep; 60(9):1210-1217. PubMed ID: 34092167
[TBL] [Abstract][Full Text] [Related]
6. The Predictive Value of CD3+/CD8+ Lymphocyte Infiltration and PD-L1 Expression in Colorectal Cancer.
Liu J; Li J; Luo F; Wu S; Li B; Liu K
Curr Oncol; 2023 Oct; 30(11):9647-9659. PubMed ID: 37999119
[TBL] [Abstract][Full Text] [Related]
7. Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes.
Williams DS; Mouradov D; Jorissen RN; Newman MR; Amini E; Nickless DK; Teague JA; Fang CG; Palmieri M; Parsons MJ; Sakthianandeswaren A; Li S; Ward RL; Hawkins NJ; Faragher I; Jones IT; Gibbs P; Sieber OM
Gut; 2019 Mar; 68(3):465-474. PubMed ID: 29382774
[TBL] [Abstract][Full Text] [Related]
8. Stage-dependent prognostic shift in mismatch repair-deficient tumors: Assessing patient outcomes in stage II and III colon cancer.
Hestetun KE; Rosenlund NB; Stanisavljević L; Dahl O; Myklebust MP
Front Oncol; 2022; 12():853545. PubMed ID: 36110945
[TBL] [Abstract][Full Text] [Related]
9. Characterisation of tumor microenvironment and prevalence of CD274/PD-L1 genetic alterations difference in colorectal Cancer.
Yang L; Liu S; He W; Xiong Z; Xia L
BMC Cancer; 2023 Mar; 23(1):221. PubMed ID: 36894899
[TBL] [Abstract][Full Text] [Related]
10. Impact of mismatch-repair deficiency on the colorectal cancer immune microenvironment.
Zhang Y; Sun Z; Mao X; Wu H; Luo F; Wu X; Zhou L; Qin J; Zhao L; Bai C
Oncotarget; 2017 Oct; 8(49):85526-85536. PubMed ID: 29156738
[TBL] [Abstract][Full Text] [Related]
11. Association of Peripheral Blood Biomarkers With Response to Anti-PD-1 Immunotherapy for Patients With Deficient Mismatch Repair Metastatic Colorectal Cancer: A Multicenter Cohort Study.
Cheng YK; Chen DW; Chen P; He X; Li PS; Lin ZS; Chen SX; Ye SB; Lan P
Front Immunol; 2022; 13():809971. PubMed ID: 35185898
[TBL] [Abstract][Full Text] [Related]
12. Tumor microenvironment classification based on T-cell infiltration and PD-L1 in patients with mismatch repair-proficient and -deficient colorectal cancer.
Liu S; Kong P; Wang X; Yang L; Jiang C; He W; Quan Q; Huang J; Xie Q; Xia X; Zhang B; Xia L
Oncol Lett; 2019 Feb; 17(2):2335-2343. PubMed ID: 30675299
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and predictive role of DNA mismatch repair status in stage II-III colorectal cancer: A systematic review and meta-analysis.
Deng Z; Qin Y; Wang J; Wang G; Lang X; Jiang J; Xie K; Zhang W; Xu H; Shu Y; Zhang Y
Clin Genet; 2020 Jan; 97(1):25-38. PubMed ID: 31432497
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and predictive roles of DNA mismatch repair status in colon cancer patients treated with oxaliplatin-based chemotherapy: a retrospective study.
Qin Q; Zhou AP; Yang L; Xu C; Sun YK; Zhang W; Wang JW; Zhong DS
J Physiol Pharmacol; 2020 Aug; 71(4):. PubMed ID: 33316771
[TBL] [Abstract][Full Text] [Related]
15. Circulating Lymphocytes, PD-L1 Expression on Tumor-infiltrating Lymphocytes, and Survival of Colorectal Cancer Patients with Different Mismatch Repair Gene Status.
Kong P; Wang J; Song Z; Liu S; He W; Jiang C; Xie Q; Yang L; Xia X; Xia L
J Cancer; 2019; 10(7):1745-1754. PubMed ID: 31205530
[TBL] [Abstract][Full Text] [Related]
16. Tumor Budding
Karlberg M; Stenstedt K; Hallström M; Ragnhammar P; Lenander C; Edler D
Anticancer Res; 2018 Aug; 38(8):4713-4721. PubMed ID: 30061240
[TBL] [Abstract][Full Text] [Related]
17. CD169
Saito Y; Fujiwara Y; Miyamoto Y; Ohnishi K; Nakashima Y; Tabata Y; Baba H; Komohara Y
Cancer Med; 2023 May; 12(9):10199-10211. PubMed ID: 36846928
[TBL] [Abstract][Full Text] [Related]
18. A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-γ.
Kikuchi T; Mimura K; Okayama H; Nakayama Y; Saito K; Yamada L; Endo E; Sakamoto W; Fujita S; Endo H; Saito M; Momma T; Saze Z; Ohki S; Kono K
Oncol Lett; 2019 Dec; 18(6):5977-5985. PubMed ID: 31788072
[TBL] [Abstract][Full Text] [Related]
19. Impact of Programmed Death-Ligand 1 Expression on Mismatch Repair Deficiency and Epstein-Barr Virus Status on Survival Outcomes in Patients with Stage II/III Gastric Cancer After Surgery.
Akimoto E; Kuwata T; Shitara K; Kawazoe A; Sakamoto N; Ishii G; Ochiai A; Kinoshita T
Ann Surg Oncol; 2023 Aug; 30(8):5227-5236. PubMed ID: 36934377
[TBL] [Abstract][Full Text] [Related]
20. Chang Wei Qing Decoction enhances the anti-tumor effect of PD-1 inhibitor therapy by regulating the immune microenvironment and gut microbiota in colorectal cancer.
Wang T; Wu L; Wang S; Shi X; Liu H; Deng W
Chin J Nat Med; 2023 May; 21(5):333-345. PubMed ID: 37245872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
